In 2023-2024, the expenditure for asthma was an estimated $1.28 billion spent on the treatment and management of asthma (out of $180.4 billion total spending on disease and injury and $98 billion spent on chronic conditions, and $5.77 billion spent on respiratory disease in 2023-2024), making asthma the third most costly respiratory condition (after COPD…
Worldwide incidence of asthma readmission is up to 40% (ref 1, intro). NSW (ref 1,3) A retrospective longitudinal study looking at 48,217 asthma hospitalisations in children aged 2-17 years reported that over 1 in 5 children hospitalised for asthma in NSW between 2007 and 2022 were readmitted for asthma within a year, costing an average…
In 2022-2023, the expenditure for asthma was an estimated $1,192 million spent on the treatment and management of asthma (out of $172 billion total health expenditure in 2022-2023), making asthma the third most costly respiratory disease after COPD and Upper respiratory conditions. Asthma expenditure included: – $378M in hospital expenditure (public ED, admitted and outpatient…